Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|March 20, 2019
Pharmacy Practice in Focus: Health Systems
- March 2019
- Volume 8
- Issue 2
The Health-System Pharmacist Role in Optimizing Outcomes for Patients Who Need DOAC Reversal Agents
Advertisement
FACULTY
James S. Kalus, PharmD, FASHP Director of Pharmacy Henry Ford Health System Detroit, Michigan
EDUCATIONAL OBJECTIVES
At the completion of this activity the participant will be able to:
- Analyze the unaddressed gaps of reversal agents for direct oral anticoagulants (DOACs) and the risk of bleeding complications
- Identify patients who are at high risk for major bleeding secondary to DOAC use
- Examine current and emerging DOAC reversal agents and their safety and efficacy
- Explore the role of the health-system pharmacist in ensuring optimal management of the patient with DOAC-associated bleeding and implementing standards of practice for reversal agents using clinical vignettes
TARGET AUDIENCE: Health-system pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: March 15, 2019
EXPIRATION DATE: March 15, 2020
ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours
FEE: This lesson is offered for free at
Articles in this issue
over 7 years ago
Use AUC to Optimize Vancomycin Dosingover 7 years ago
Approach Respiratory Illnesses Rationallyover 7 years ago
Manage Acute Pain in Those Using Opioidsover 7 years ago
Documenting 340B Value Is Key to Successover 7 years ago
Panelists Discuss Challenges of Diagnosing HEover 7 years ago
News and Trends March 2019over 7 years ago
Perform an AOR to Comply With USPover 7 years ago
Enterprise Collaborations Help Meet Challengesover 7 years ago
Cancer Pain Treatment Remains a Challengeover 7 years ago
Here Is What to Know About Vaccines for SeniorsAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
2
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
3
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
4
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
5